Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2025-10-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于子公司注射用GenSci139境内生产药品临床试验获批的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a clinical trial for a drug developed by its subsidiary. It details the drug's characteristics, the approval from the National Medical Products Administration, and the potential impact and risks. The document is relatively short (1472 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it provides substantive information about the clinical trial approval. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-10-20 Chinese
关于子公司注射用GenSci143境外生产药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High-tech Industry Group Co., Ltd. regarding the acceptance of a clinical trial application for a drug (GenSci143) by the US FDA. It details the drug's characteristics, the regulatory acceptance, and potential risks. The document is short (1549 characters) and serves as an announcement of a regulatory event related to clinical trial approval. It does not contain financial data, management discussion, or detailed report content. It is not a financial report, earnings release, or management report. It is a regulatory announcement about a clinical trial application acceptance, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-10-17 Chinese
关于子公司三价流感病毒裂解疫苗（BK-01佐剂）临床试验申请获得批准的公告
Regulatory Filings Classification · 100% confidence The document is an official announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the approval of a clinical trial application for a subsidiary's vaccine product by the National Medical Products Administration. It contains no financial data, no financial statements, and no detailed report content. The document is a regulatory announcement about a clinical trial approval, which is a typical regulatory filing. The document length is short (1612 characters), and it is clearly an announcement rather than a full report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS).
2025-10-13 Chinese
关于子公司吸附无细胞百白破b型流感嗜血杆菌联合疫苗临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the approval of a clinical trial application for a vaccine by its subsidiary. It includes details about the clinical trial approval notice, vaccine description, impact on the company, and risk warnings. The document is relatively short (1712 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is a regulatory announcement about a clinical trial approval, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-09 Chinese
关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Changchun High-tech Industry Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, compliance with regulatory requirements, and references previous announcements about the repurchase plan. The document does not contain full financial statements or comprehensive financial analysis but focuses on the status update of the share buyback activity. This matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback of its own shares. The document length is short (1398 characters), and it is not merely an announcement of a report but contains substantive information about the repurchase progress.
2025-10-09 Chinese
关于子公司替勃龙片在境内获批上市的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the approval of a subsidiary's drug (Tibolone tablets) for domestic market listing by the National Medical Products Administration. It details the drug's registration certificate, basic information, clinical trial results, and potential impact on the company. The document is short (1146 characters) and serves as a regulatory announcement about a product approval, not a financial report, management change, or shareholder meeting material. It does not contain financial statements or earnings data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.